L7 Informatics Automates Lab Operations and Supports Washington University School of Medicine with Workflow for Its Saliva-based COVID-19 Test

AUSTIN, Texas, Nov. 9, 2020 /PRNewswire/ — L7 Informatics announced that it has deployed L7|ESP to automate all lab operations starting with COVID-related workflow at the Genome Technology Access Center ([email protected]) in the McDonnell Genome Institute at the Washington University School of Medicine. The COVID-related workflow supports the new saliva test, developed by Washington University researchers, that is used to detect the SARS-CoV-2 virus.

L7 Informatics, provides software and services that enable synchronized solutions for scientific research and development. L7’s Enterprise Science Platform (ESP) is a scientific information management (SIM) solution that enables crop science companies to connect wet lab, greenhouses, sequencing and analytical processes with instruments and software systems to accelerate research and drive organizational efficiency. (PRNewsfoto/L7 Informatics, Inc.)

L7|ESP is CLIA (Clinical Laboratory Improvement Amendments) compliant and enables diagnostic organizations to use a single platform for registering and processing samples, running complex analyses, generating reports, and provides complete end-to-end assay automation. L7|ESP is designed to increase reproducibility and efficiency while decreasing errors and turnaround time.

According to L7 Informatics President and CEO, Vasu Rangadass, Ph.D., “L7|ESP will enable the COVID-related workflow at Washington University’s McDonnell Genome Institute (MGI) to scale to 10,000 samples per week if need be, and this ability to scale-up could help support the number of tests that can be conducted.”

L7 carried out the content implementation at GTAC in four releases. The main tasks performed as part of this project include Sample Accessioning, Saliva Processing, RT/STA, Prepare and Load IFC Plate, Analysis/ Reporting, Inventory App, Protocols/workflows/workflow chain configs, and Locations App.

Richard Head, a professor of genetics and director of the Genome Technology Access Center at the McDonnell Genome Institute, added, “This is a COVID-19 test process that can be used at scale, and it is essential that test results are reproducible and samples can be processed efficiently. We have used L7’s ESP technology to help us reach that goal.” 

About L7 Informatics
The L7 mission is to revolutionize the scientific process by streamlining process and data management and thereby accelerate precision health across life sciences, healthcare, and food value-chains. L7 Informatics provides software and services that enable synchronized solutions for scientific research and development. For more information, visit www.L7informatics.com.

Media Contact
Jessica Tobey
L7 Informatics, Inc.
[email protected]


Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/l7-informatics-automates-lab-operations-and-supports-washington-university-school-of-medicine-with-workflow-for-its-saliva-based-covid-19-test-301168894.html

SOURCE L7 Informatics, Inc.

Source Article

Read More

Humanigen Announces First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVID-19

Humanigen, Inc. (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with lenzilumab, today announced that MedStar Washington Hospital Center in Washington, D.C. treated its first COVID-19 patient with lenzilumab. The primary goal of this Phase 3 randomized, double-blind, multicenter, placebo-controlled clinical trial is to determine if lenzilumab can help hospitalized patients with COVID-19 recover faster. As many as 89% of hospitalized patients with COVID-19 are at risk of a complication called cytokine storm, a harmful inflammation that has been the leading cause of COVID-19 death. MedStar Washington Hospital Center is one of 18 sites in the U.S. approved to enroll eligible patients to study lenzilumab, designed specifically to stop this storm. Eligible patients can participate in this trial while also receiving other standard-of-care therapies as recommended by their treating physician.

“Given the growing number of cases in the D.C. area seen in the past few weeks, we were particularly motivated to ensure our Phase 3 study was enrolling and accessible,” said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. “We have been impressed with the hospital leadership and trial investigators at MedStar Washington, and worked together with speed and efficiency to get this trial location ready to enroll patients.”

For more information on participating in the Phase 3 COVID-19 trial of lenzilumab, please visit StopStorm.com, and talk to your doctor to see if you may be eligible to participate.

More details on Humanigen’s programs in COVID-19 can be found on the Company’s website at www.humanigen.com under the COVID-19 tab, and details of the U.S. Phase 3 potential registration study can be found at clinicaltrials.gov using Identifier NCT04351152.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company’s immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab™ as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical

Read More

COVID-19 activity intensifying in Washington

SEATTLE (AP) — State health officials say a new COVID-19 report shows an increase in cases and hospitalizations throughout Washington.

If not brought under control, officials said the spike could jeopardize progress toward reopening schools, strain the health care system and increase risks during the holiday season.

In an updated situation report released Wednesday, the state Department of Health said the virus is spreading faster in Western Washington than Eastern Washington, but is rising on both sides of the Cascades.

Estimates show each new COVID-19 patient is infecting 1.34 others, on average, in Western Washington. In Eastern Washington the average infection rate is 1.12. The goal is a number well below one, which would mean COVID-19 transmission is declining, officials said.

“High rates in the community increase the chance that someone at your gathering — even people you know well and trust —could have COVID-19,” Deputy Secretary of Health Lacy Fehrenbach said in a news release. “If we act now, we can get these increases in control in time for the holidays.”

Recent growth in cases is widely distributed across the state. Several larger counties including Clark, Pierce, Snohomish and Thurston are seeing steady growth in cases. After increases through Oct. 7, King County case counts began to decline, possibly because of decreased testing in that time period.

Health officials say the trends can be reversed if everyone wears a mask around people they don’t live with and limits the number, size and frequency of gatherings.

Since the pandemic began, more than 104,000 COVID-19 cases have been confirmed in the state. The state dashboard shows 2,337 people with confirmed cases in the state have died.

Source Article

Read More

Washington Offering Free Flu Shots To Uninsured Adults

WASHINGTON — This year’s flu season has been very mild, and state health officials would like to keep it that way.

The Washington State Department of Health has announced a new program, offering free flu shots to uninsured adults at 23 participating Albertsons and Safeway pharmacies across the state.

To qualify for a free shot, patients must be over 18 and uninsured. No proof of residency or immigration status will be required. Flu vaccines are already being offered and the program will run through June of 2021.

Participating Pharmacies in Western Washington



Phone Number

Safeway Pharmacy (Store #1546)

221 West Heron Street
Aberdeen, WA 98520

(360) 532-8743

Safeway Pharmacy (Store #0531)

101 Auburn Way S
Auburn, WA 98002

(253) 735-4404

Safeway Pharmacy (Store #3285)

1275 E Sunset Drive
Bellingham, WA 98226

(360) 650-1537

Safeway Pharmacy (Store #1467)

900 N Callow
Bremerton, WA 98312

(360) 792-9262

Safeway Pharmacy (Store #0474)

1715 Broadway
Everett, WA 98201

(425) 339-9448

Safeway Pharmacy (Store #1484)

4128 Rucker Ave
Everett, WA 98203

(425) 258-3552

Safeway Pharmacy (Store #1294)

210 Washington Ave S
Kent, WA 98032

(253) 852-5115

Safeway Pharmacy (Store #1464)

3215 Harrison Avenue NW
Olympia, WA 98502

(360) 956-3827

Safeway Pharmacy (Store #1492)

110 East 3rd Street
Port Angeles, WA 98362

(360) 457-0599

Safeway Pharmacy (Store #1563)

200 S 3rd Street
Renton, WA 98057

(425) 226-0325

Safeway Pharmacy (Store #1508)

3820 Rainier Avenue South
Seattle, WA 98118

(206) 725-9887

Safeway Pharmacy (Store #3213)

15332 Aurora Ave N
Shoreline, WA 98133

(206) 539-5500

Safeway Pharmacy (Store #0329)

1112 South M Street
Tacoma, WA 98405

(253) 627-8840

Safeway Pharmacy (Store #1437)

1302 E 38th Street
Tacoma, WA 98418

(253) 471-1630

Learn more about the program from the Washington State Department of Health’s website.

Washington’s top health officials say, in the middle of a pandemic, the last thing our medical system needs is an influx of flu patients.

“The potential for a severe influenza season, or even an average influenza season, compounding the COVID outbreak is very, very disturbing and worrisome,” said King County Health Officer Dr. Jeff Duchin.

Read more: Health Experts: Now ‘More Important Than Ever’ To Get Flu Vaccine

The flu shot is recommended for everyone six months old or older. Patients over 65 should consult with their doctor first.

The Washington State Department of Health says there are several changes patients should be aware of for the 2020-2021 flu season:

  • All children under 19 can now receive flu vaccines and other recommended vaccines for free.

  • Most insurance plan cover the cost of the flu vaccine for adults.

  • Adults without insurance may qualify to recieve the vaccine at no cost. Find more information on free vaccination from your local health department.

Guidance from the Center for Disease Control and Prevention shows the best time to get vaccinated is between September and October, though if the flu season persists past October it’s never too late to get the vaccine. Receiving a vaccine too early, like in August or July, can leave it

Read More

Washington blood donors urged to help amid surge in hospital usage

This year’s blood supplies aren’t quite keeping pace with the needs of local hospitals around the Seattle area, according to Bloodworks Northwest officials.

Bloodworks officials noted requests for blood donations are up 120% of normal as of early October, particularly for type O blood. As need increases, so too does pressure on the current supply for even common surgical procedures, making the need for more donors relatively urgent this month within Pacific Northwest hospitals.

This month, blood donors can learn if they have COVID-19 antibodies that may help patients currently fighting coronavirus because Bloodworks is testing all whole blood donations for COVID-19 antibodies through Oct. 31 in conjunction with pandemic response efforts. A positive test result indicates if the donor’s immune system has produced antibodies to SARS-CoV2 (COVID-19) regardless of whether the person ever showed symptoms.

Bloodworks Northwest is backed by 75 years of Northwest history and 250,000 donors. The local, non-profit remains an independent, volunteer-supported and community-based organization and leader in transfusion medicine.

With patients across hospitals in Washington, Oregon and Alaska, Bloodworks partners closely with local hospitals to deliver a high level of patient care among blood components, complex cross-matching, specialized lab services for organ transplants, care for patients with blood disorders, and collection of cord blood stem cells for cancer treatment.

Many patients with traumatic injuries, undergoing surgeries or organ transplantation, or receiving treatment for cancer and blood disorders fall dependent on Bloodworks’ services, especially among an already trying year given the expanse of the novel coronavirus.

“Hospitals are seeing an increase in traumas, transplants, and emergency situations requiring blood,” said Bloodworks President and CEO, Curt Bailey. “Overall blood usage is up 20% which translates to an additional 600 units of blood needed each week. This is unsustainable unless more community members step up to fill these growing needs of our hospitals and those lives depending on them.”

To fill the need, it typically takes around 1,000 people each day to make appointments and give blood at Bloodworks donor centers and pop-up blood drives happening throughout Western Washington and Oregon, according to Bloodworks.

“As this high usage trend continues, our deficit increases with our most-needed Type O blood types fast approaching critically low levels,” said Vicki Finson, executive vice president of blood services. “Local hospitals are counting on all of us to meet their commitment to provide the best patient care possible.  Whether you’re a first-time donor or longtime donor, please make an appointment now to keep our shelves stocked for patients.”

Notably, donations alongside Bloodworks provide 95% of the lifesaving blood supply to Pacific Northwest hospitals, according to Bloodworks officials.

So whether you have a spare hour to check in and enjoy a post-donation cookie, or are searching for ways to help hospitals amid COVID-19, check out information about who can donate and where, available here.

As of late, they’ve launched pop-up locations across Bellevue, Bellingham, Central Seattle, Everett, Federal Way, Lynnwood, Olympia, North Seattle, Silverdale, Tukwila, Vancouver and Eugene, Oregon.

Appointments and masks are required,

Read More

Washington residents warned of drug surge, fentanyl dangers

SPOKANE, Wash. (AP) — Federal and state officials have warned residents in eastern Washington about the dangers of illicit synthetic opioids after multiple teenagers died in recent weeks.

U.S. Attorney William Hyslop said the community is facing a “growing and increasing influx of deadly fentanyl into eastern Washington,” The Spokesman-Review reported Wednesday.

Data from the U.S. Drug Enforcement Agency shows that seizures of fentanyl, which is 50 to 100 times more powerful than morphine, have increased by about 200% compared to last year.

DEA special agent Keith Weis said the drug is often smuggled over the border from Mexico, where it is produced at a much cheaper cost than heroin and cut into a pill form without dosage regulations. The drug then reaches distribution networks including in the Tri-Cities.

Fentanyl is a potent drug that can become fatal with as little as 2 milligrams. Anyone who is exposed to the drug could experience breathing effects, including shortness of breath or not breathing, at a much lower dosage than a usual medical dose.

Hyslop announced Wednesday that the U.S. attorney’s office, the drug enforcement agency, local law enforcement and school districts have collaborated to create a public campaign warning families of the danger posed by fentanyl and other opioids.

“Here in Spokane, we’re seeing a lot of these fentanyl pills being stamped as OxyContin pills,” Spokane Police Chief Craig Meidl said. “Now, we’re seeing these pills being stamped into the shape of baby aspirin as well.”

Fentanyl falls under the same criminal category as methamphetamine, cocaine and OxyContin under federal drug laws, Hyslop said, adding that police do not believe they can “arrest our way out of this.”

“This is greater. This is a community issue,” he said. “This requires everybody to be involved.”

Source Article

Read More